Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TP-1 is a polysaccharide isolated from the Huaier fungus. It has demonstrated significant inhibitory effects on the growth, adhesion, migration, and motility of human hepatocellular carcinoma (HCC) SMMC-7721 cells in a dose-dependent manner. TP-1 achieves its effects by decreasing the messenger RNA (mRNA) and protein levels of RNA-binding factor 1 (AUF-1) and astrocyte elevated gene-1 (AEG-1), while simultaneously increasing the expression of microRNA-122 (miR-122). Furthermore, it modulates epithelial-mesenchymal transition markers by increasing E-cadherin protein expression and decreasing N-cadherin protein levels. Preclinical studies have shown that TP-1 significantly inhibits lung metastasis of liver cancer in orthotopic SMMC-7721 tumor-bearing mice, suggesting its potential as a powerful chemopreventive agent against HCC metastasis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TP-1.